Compare Moderna, Inc. (MRNA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Neurocrine Biosciences Inc — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | NBIX | |
|---|---|---|
Market Cap | $23.60B | $17.40B |
Sector | Health | Health |
52-Week High | $81.80 | $180.55 |
52-Week Low | $22.36 | $123.10 |
Enterprise Value | $19.70B | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
